Abhijit “Ron” Mazumder has almost thirty years of experience working with biomarkers, technologies, and computational approaches for pharmaceutical and diagnostics programs. After leading the development of genomics technologies and novel platforms for several biotech companies, he worked for Johnson and Johnson and Merck, where he developed diagnostics and companion diagnostics and pharmacodynamic and predictive biomarkers. From October 2016 to January 2023, Ron was Vice President and Global Head of Oncology Biomarker Development and Companion Diagnostics at Genentech, leading a team that worked in pre-clinical, early clinical and late clinical development phases. He joined Illumina Ventures as a Partner in January 2023 and currently serves on the Boards of Walking Fish Therapeutics, Actym Therapeutics and Kodikaz Therapeutic Solutions. Ron also serves on the Advisory Board for Biomedical Engineering at The Johns Hopkins University. He obtained his B.A. from The Johns Hopkins University, his PhD from the University of Maryland, and his MBA from Lehigh University.